2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, MDS, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4287 Disease status at allogeneic hematopoietic cell transplantation, rather than conditioning intensity, total body irradiation, or post-transplant cyclophosphamide, determines outcomes in mycosis fungoides and Sézary syndrome: An EBMT lymphoma working party analysis

Federico Mazzon, MD, Aleksandr Lazaryan, MD MPH PhD2, Mathilde Fekom, PhD3, Diane Bacabac4, Jane Felicity Apperley, FRCP, FRCPath, MB5, Giorgia Saporiti, MD6, Regis Peffault De Latour, MD, PhD7, Tim J.A. Dekker, MD, PhD8, Sridhar Chaganti, MD, PhD, FRCPath, MRCP9, Catherine Flynn10, Carlos Manuel Panizo Santos, MD11, Dominik Schneidawind, MD, PhD12, Rodrigo Martino, MD13, Edouard Forcade, MD, PhD14, Chama Mokeddem, MD15, Helene Labussiere Wallet16, Raynier Devillier, PhD17, Tobias Gedde-Dahl18, Irma Khvedelidze19, Gandhi Damaj, MD, PhD20, Norbert Schmitz21, Ali Bazarbachi, MD, PhD22
1 Moffitt Cancer Center, Tampa, United States
2 Moffitt Cancer Center, Tampa, United States
3 European Society for Blood and Marrow Transplantation (EBMT), Paris Study Unit, Hôpital Saint-Antoine, Paris, France
4 European Society for Blood and Marrow Transplantation (EBMT), Paris Study Unit, Hôpital Saint-Antoine, Paris, France
5 Imperial College Hammersmith London, London, United Kingdom
6 Fondazione IRCCS - Ca Granda,, Milan, Italy
7 Saint-Louis Hospital, BMT Unit, Paris, France
8 Leiden University Medical Center, Leiden, Netherlands
9 Birmingham Centre for Cellular Therapy and Transplant (BCCTT), Birmingham, United Kingdom
10 Hope Directorate - St. James's Hospital, Dublin, Ireland
11 Hospital Universitario Donostia, San Sebastian, Spain
12 University Hospital Zurich, Zurich, Switzerland
13 Hospital Santa Creu i Sant Pau, Barcelona, Spain
14 CHU Bordeaux, Hopital Haut-Leveque, Pessac, France
15 Maladies du Sang CHU Angers FHU Goal, Angers, France
16 Centre Hospitalier Lyon Sud, Pierre Benite cedex, France
17 Programme de Transplantation&Therapie Cellulaire, Marseille, France
18 Oslo University Hospital, Rikshospitalet, Oslo, Norway
19 European Society for Blood and Marrow Transplantation (EBMT), Paris Study Unit, Hôpital Saint-Antoine, Paris, France
20 Haematology Institute and University of Caen, CRNS, ISTCT UMR6030, GIP Cyceron, Caen, France
21 Department of Medicine A, Hematology and Oncology, University Hospital of Muenster, Muenster, Germany
22 Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon

Background: Allogeneic hematopoietic cell transplantation (alloHCT) remains the only potentially curative therapy for advanced mycosis fungoides (MF) and Sézary syndrome (SS). However, uncertainty remains regarding the optimal conditioning intensity, use of total body irradiation (TBI), and incorporation of post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis. We sought to determine whether these transplant-related factors influence outcomes and whether their effects differ according to disease status at alloHCT.
Methods: We analyzed European Society for Blood and Marrow Transplantation (EBMT) registry patients with MF or SS undergoing alloHCT. An initial registry-level analysis included patients transplanted in complete remission (CR), partial remission (PR), or refractory/progressive disease (Ref/PD) to evaluate the prognostic impact of disease status at transplantation. Patients transplanted in CR or PR comprised the prespecified primary analytic cohort for comparative analyses of conditioning intensity, total body irradiation (TBI), and post-transplant cyclophosphamide (PTCy). Multivariable Cox and competing-risk models evaluated overall survival (OS), progression-free survival (PFS), relapse incidence (RI), non-relapse mortality (NRM), acute and chronic GVHD, and GVHD-free relapse-free survival (GRFS). Models adjusted for age, disease status, conditioning intensity (myeloablative conditioning [MAC] vs reduced-intensity/non-myeloablative conditioning [RIC/NMA]), TBI use, time from diagnosis to alloHCT, and PTCy exposure. Prespecified interaction analyses evaluated disease status × conditioning intensity and disease status × TBI. Separate multivariable analyses were performed within the CR and PR cohorts.
Results: A total of 413 patients comprised the primary analytic cohort, including 269 (65%) with MF and 144 (35%) with SS, representing, to our knowledge, the largest single-cohort alloHCT analysis of MF and SS to date. At alloHCT, 118 (29%) patients were in CR and 295 (71%) in PR. Median age at alloHCT was 53 years, 22% received TBI, and 16% received PTCy-based GVHD prophylaxis. Disease status at alloHCT emerged as the dominant determinant of outcome. In the broader registry cohort, patients transplanted with Ref/PD experienced significantly inferior OS (HR 1.63, 95% CI 1.15–2.31; p=0.006), PFS (HR 1.72, 95% CI 1.28–2.32; p<0.001), RI (HR 1.92, 95% CI 1.36–2.73; p<0.001), and GRFS (HR 1.71, 95% CI 1.30–2.24; p<0.001) compared with those transplanted in CR. Within the CR/PR primary analytic cohort, outcomes remained directionally consistent, with patients transplanted in PR demonstrating inferior GRFS (HR 1.64, 95% CI 1.19–2.26; p=0.002) and a trend toward increased RI compared with those transplanted in CR (HR 1.46, 95% CI 0.99–2.15; p=0.056). Conditioning intensity was not independently associated with OS, PFS, RI, NRM, GVHD outcomes, or GRFS. Importantly, no significant interaction between disease status and conditioning intensity was observed for OS (p-interaction=0.086), PFS (p=0.5), RI (p>0.9), NRM (p=0.11), or GRFS (p=0.3), providing no evidence that patients transplanted in PR derived greater benefit from myeloablative conditioning. Likewise, TBI was not independently associated with major outcomes, and no significant disease status × TBI interaction was identified across study endpoints. After multivariable adjustment, PTCy use was not associated with OS (HR 1.15, p=0.5), PFS (HR 1.10, p=0.6), RI (HR 1.16, p=0.5), NRM (HR 0.91, p=0.8), chronic GVHD, extensive chronic GVHD, or GRFS (HR 0.96, p=0.8). Findings remained consistent in separate CR-only and PR-only analyses. In CR patients, exploratory trends toward reduced chronic GVHD (HR 0.38, p=0.076) and increased RI (HR 2.08, p=0.058) were observed with PTCy.
Conclusion: Disease status at alloHCT emerged as the dominant determinant of outcome in MF and SS, with progressively inferior outcomes observed from CR to PR to Ref/PD. Neither conditioning intensity, TBI, nor PTCy modified this prognostic hierarchy. Importantly, no evidence of effect modification by disease status was observed for conditioning intensity or TBI across any major endpoint. These findings suggest that achieving optimal disease control before alloHCT may be more important than intensifying transplantation strategies and support the use of less toxic transplantation approaches without compromising outcomes of patients with MF and SS undergoing alloHCT.

Federico Mazzon, MD: No relevant conflicts of interest to declare.